Chronic kidney disease: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• SGLT2 24
• GLP-1 8
• NLRP3 0
• NRF2 1
• PI3K 0
• APOL1 3
• AKT 0
• STAT3 1
• mTOR 1
• PPAR 0
• AMPK 0
• SIRT1 0
• HIF-1 0
• TLR4 0
• STING 0
• MAPK 0
• CTNNB1 0
• TP53 0
• ERK 0
• GPX4 0
• IL-6 3
• VEGF 0
• IL-1 1
• JAK 0
• JNK 0
• TNF 1
• DPP-4 0
• EGFR 0
• YAP 0
• FGFR 0
• PCSK9 0
• APOE 0
• PINK1 0
• TFEB 0
• BCMA 3
• HMGB1 0
• HSP90 0
• BDNF 0
• GIP 0
• CD40 0
• CD47 0
• COX-2 0
• IL-17 1
• PKM2 0
• PSMA 0
• ABL1 0
• CCR5 0
• EZH2 0
• METTL3 0
• MMP-9 0
• PKD1 0
• PTEN 0
• SNCA 0
• ANGPTL3 0
• BCL-2 0
• CD19 1
• CD38 0
• CDK4/6 0
• CXCR4 0
• FTO 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering the gene regulation of oxygen homeostasis and human fitness (ErythrO2Reg)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €1,500,000· until Mar 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Next-generation therapeutics for vascular diseases (TIE2gether)

  Helsingin Yliopisto· Helsinki, Finland· EU contribution €4,273,568· until Jan 2031· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Formaldehyde crosslink exposure and genomic ageing (FORCE)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €2,693,628· until Dec 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Early Inflammation in Fibrotic Niches of Chonic Kidney Disease (InFibrosis)

  Universite Paris Cite· Paris, France· EU contribution €1,498,100· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Direct implication of the Calcium Sensing Receptor in Vascular Calcifiction and Atherosclerosis in Chronic Kidney Disease (AtheroCaSR)

  Cardiff University· Cardiff, United Kingdom· EU contribution €325,435· until Feb 2029

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Targeting Glutamine (Q) Metabolism in the Renal Ciliopathies (QrCiliopathies)

  Ospedale San Raffaele Srl· Milano, Italy· EU contribution €150,000· until Jan 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Transforming Haemodialysis Safety with a Graphene Light-Activated Antimicrobial Device (SAFE-HD)

  GO Antimicrobial Technologies, Lda· Porto, Portugal· EU contribution €500,000· until Jul 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  LOKI: Loiasis-associated chronic kidney disease – towards clinical recognition and policy action

  Institut de Recherche Pour Le Developpement· Marseille, France· EU contribution €150,000· until Nov 2027

• European Commission (Horizon Europe) · HORIZON-RIA

  Mechanism-Informed Multimodal Generative AI for Causal and Dynamical Modelling in Biomedical Research (AIRIS)

  Athina-Erevnitiko Kentro Kainotomias Stis Technologies Tis Pliroforias, Ton Epikoinonion Kai Tis Gnosis· Maroussi, Greece· EU contribution €16,944,729· until May 2030· 11 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  From uremic toxins to cognitive decline: Elucidating the pathophysiology of mild cognitive impairment in chronic kidney disease (MOMENTUM)

  BIOGEM scarl· Ariano Irpino (Av), Italy· EU contribution €5,999,488· until May 2030· 10 countries

10 of 52 running projects, newest first. Listed amounts together: €145.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 29
• Organoids 10
• Mendelian Randomization Analysis 78
• CRISPR-Cas Systems 5
• Gene Expression Profiling 88
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 2
• Exome Sequencing 19
• Proteomics 103
• Metabolomics 91
• Mass Spectrometry 18
• Flow Cytometry 10
• Immunohistochemistry 19
• Liquid Biopsy 2
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 70
• Machine Learning 176
• Deep Learning 22
• Cohort Studies 553
• Genome-Wide Association Study 79

• Elevated glucose in kidney organoids induces tissue-intrinsic inflammation driving epithelial detachment.

  Stem Cell Reports, Sept 2026

• Podocyte injury damages podocytes in chimeric organoids.

  PLoS One, Aug 2026

• Modelling ischaemic AKI in human kidney organoids reveals injury-associated epithelial states and macrophage-epithelial crosstalk.

  Genome Med, Aug 2026

• Human Kidney Organoids to Uncover Preterm Birth-Associated Low Nephron Endowment.

  Nephron, May 2026

• Bridging Kidney Organoid Innovation and Regenerative Medicine: Current Advances and Future Directions.

  Cell Prolif, May 2026

• Induction of fibrosis in human kidney organoids delineates mechanisms and therapeutic targets of fibrotic kidney disease.

  Stem Cell Res Ther, Apr 2026

• Vascularization and maturation of kidney organoids: a comprehensive review of technological trends and challenges.

  J Artif Organs, Feb 2026

• Analysis of high glucose injury using human induced pluripotent stem cell-derived kidney organoids.

  BMC Nephrol, Jan 2026

• Splice modulation of COL4A5 reinstates collagen IV assembly in an organoid model of Alport syndrome.

  JCI Insight, Dec 2025

• Modeling kidney fibrosis and tubular regeneration in iPSC-derived kidney organoids.

  Stem Cell Res Ther, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.